3/16
09:46 pm
fulc
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk [Yahoo! Finance]
3/6
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/3
08:42 am
fulc
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
3/3
08:30 am
fulc
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Medium
Report
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
2/25
10:35 am
fulc
Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics move lower ‘overdone,' says Stifel [Yahoo! Finance]
2/24
06:04 pm
fulc
Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.
Medium
Report
Fulcrum Therapeutics (FULC) had its "outperform" rating reaffirmed by Leerink Partners.
2/24
03:07 pm
fulc
Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.
Medium
Report
Fulcrum Therapeutics (FULC) was given a new $17.00 price target by Truist Financial Corporation.
2/24
12:17 pm
fulc
Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Fulcrum Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
07:01 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
High
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
2/24
07:00 am
fulc
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
High
Report
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
2/17
08:00 am
fulc
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Low
Report
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
2/6
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/12
08:04 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $20.00 price target on the stock.
1/9
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/7
08:00 am
fulc
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/21
07:42 am
fulc
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]
Medium
Report
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study [Yahoo! Finance]